HK1027040A1 - Molecular dispersion composition with enhanced bioavailability. - Google Patents

Molecular dispersion composition with enhanced bioavailability.

Info

Publication number
HK1027040A1
HK1027040A1 HK00106351A HK00106351A HK1027040A1 HK 1027040 A1 HK1027040 A1 HK 1027040A1 HK 00106351 A HK00106351 A HK 00106351A HK 00106351 A HK00106351 A HK 00106351A HK 1027040 A1 HK1027040 A1 HK 1027040A1
Authority
HK
Hong Kong
Prior art keywords
dispersion composition
molecular dispersion
enhanced bioavailability
bioavailability
enhanced
Prior art date
Application number
HK00106351A
Other languages
English (en)
Inventor
Surendra A Sangekar
Ping I Lee
Amin A Nomeir
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1027040A1 publication Critical patent/HK1027040A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK00106351A 1997-12-22 2000-10-09 Molecular dispersion composition with enhanced bioavailability. HK1027040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99716897A 1997-12-22 1997-12-22
PCT/US1998/026218 WO1999032118A1 (en) 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability

Publications (1)

Publication Number Publication Date
HK1027040A1 true HK1027040A1 (en) 2001-01-05

Family

ID=25543717

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00106351A HK1027040A1 (en) 1997-12-22 2000-10-09 Molecular dispersion composition with enhanced bioavailability.

Country Status (28)

Country Link
EP (1) EP1039908B1 (cs)
JP (2) JP2001526227A (cs)
KR (1) KR100597331B1 (cs)
CN (1) CN1116039C (cs)
AR (1) AR017436A1 (cs)
AT (1) ATE260105T1 (cs)
AU (1) AU761994C (cs)
BR (1) BR9813728A (cs)
CA (1) CA2315685C (cs)
CO (1) CO4970793A1 (cs)
CZ (1) CZ295956B6 (cs)
DE (1) DE69821984T2 (cs)
DK (1) DK1039908T3 (cs)
ES (1) ES2214757T3 (cs)
HK (1) HK1027040A1 (cs)
HU (1) HU229052B1 (cs)
ID (1) ID28304A (cs)
IL (1) IL136460A0 (cs)
MY (1) MY126580A (cs)
NO (1) NO327383B1 (cs)
NZ (1) NZ504834A (cs)
PE (1) PE20000012A1 (cs)
PL (1) PL192423B1 (cs)
PT (1) PT1039908E (cs)
SK (1) SK285662B6 (cs)
TW (1) TW527196B (cs)
WO (1) WO1999032118A1 (cs)
ZA (1) ZA9811592B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1492508A4 (en) * 2002-03-04 2009-05-06 Teva Pharma DOSAGE FORMS WITH CONTROLLED RELEASE
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PT103661B (pt) 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
JPH0848632A (ja) * 1994-08-08 1996-02-20 Kanebo Ltd エトポシドを含有する固形組成物および固形製剤
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
ES2224256T3 (es) * 1996-06-28 2005-03-01 Schering Corporation Disolucion solida de un agente antifungico con biodisponibilidad mejorada.

Also Published As

Publication number Publication date
EP1039908B1 (en) 2004-02-25
CO4970793A1 (es) 2000-11-07
NO20003235D0 (no) 2000-06-21
EP1039908A1 (en) 2000-10-04
CZ20002304A3 (cs) 2001-04-11
SK8962000A3 (en) 2001-07-10
CZ295956B6 (cs) 2005-12-14
KR20010033397A (ko) 2001-04-25
DK1039908T3 (da) 2004-05-03
KR100597331B1 (ko) 2006-07-10
AU761994C (en) 2004-01-08
ZA9811592B (en) 1999-06-17
SK285662B6 (sk) 2007-05-03
WO1999032118A1 (en) 1999-07-01
AU761994B2 (en) 2003-06-12
ID28304A (id) 2001-05-10
NO20003235L (no) 2000-07-27
CA2315685A1 (en) 1999-07-01
JP2010059212A (ja) 2010-03-18
DE69821984T2 (de) 2004-12-30
CA2315685C (en) 2008-02-05
PE20000012A1 (es) 2000-01-18
PL341344A1 (en) 2001-04-09
ES2214757T3 (es) 2004-09-16
HU229052B1 (en) 2013-07-29
ATE260105T1 (de) 2004-03-15
CN1116039C (zh) 2003-07-30
PT1039908E (pt) 2004-06-30
BR9813728A (pt) 2000-10-10
MY126580A (en) 2006-10-31
CN1282245A (zh) 2001-01-31
NZ504834A (en) 2001-12-21
DE69821984D1 (de) 2004-04-01
IL136460A0 (en) 2001-06-14
NO327383B1 (no) 2009-06-22
AU1814399A (en) 1999-07-12
AR017436A1 (es) 2001-09-05
HUP0100850A2 (hu) 2001-10-28
PL192423B1 (pl) 2006-10-31
TW527196B (en) 2003-04-11
JP2001526227A (ja) 2001-12-18
HUP0100850A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
CY2433B1 (en) Interferon conjugates.
ZA984849B (en) Compositions.
ZA9811886B (en) Novel polymers.
HK1016976A1 (en) Resorcinyl-triazine.
HK1027957A1 (en) Pharmaceutical composition.
ZA991272B (en) Novel thiobenzamides.
ZA9811504B (en) Novel pharmaceutical.
ZA989680B (en) Pharmaceutical composition.
ZA9811506B (en) Novel pharmaceutical.
ZA981926B (en) Detergent--package combination.
ZA992072B (en) Substituted pyrroles.
DE59804842D1 (en) Aliphatische, emissionsarme, sinterfähige thermoplastische polyurethanformmassen
ZA987055B (en) Substituted 4-benzoylpyrazoles.
ZA9811505B (en) Novel pharmaceutical.
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA9811502B (en) Novel composition.
HK1027040A1 (en) Molecular dispersion composition with enhanced bioavailability.
ZA974428B (en) Antifungal composition with enhanced bioavailability.
ZA987392B (en) Pharmaceutical composition.
ZA982436B (en) Thiazolimine derivatives.
HK1017834A1 (en) Bodyshaper.
HK1038009A1 (en) Tricyclic delta3-piperidines as pharmaceuticals.
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA987B (en) Substituted 4-benzoylpyrazoles.
ZA988206B (en) Piperidinylmethyloxazolidinone derivative.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141217